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Abstract
IMPORTANCE—Mutations in known causal Alzheimer disease (AD) genes account for only 1% 
to 3% of patients and almost all are dominantly inherited. Recessive inheritance of complex 
phenotypes can be linked to long (>1-megabase [Mb]) runs of homozygosity (ROHs) detectable 
by single-nucleotide polymorphism (SNP) arrays.
OBJECTIVE—To evaluate the association between ROHs and AD in an African American 
population known to have a risk for AD up to 3 times higher than white individuals.
DESIGN, SETTING, AND PARTICIPANTS—Case-control study of a large African American 
data set previously genotyped on different genome-wide SNP arrays conducted from December 
2013 to January 2015. Global and locus-based ROH measurements were analyzed using raw or 
imputed genotype data. We studied the raw genotypes from 2 case-control subsets grouped based 
on SNP array: Alzheimer’s Disease Genetics Consortium data set (871 cases and 1620 control 
individuals) and Chicago Health and Aging Project–Indianapolis Ibadan Dementia Study data set 
(279 cases and 1367 control individuals). We then examined the entire data set using imputed 
genotypes from 1917 cases and 3858 control individuals.
MAIN OUTCOMES AND MEASURES—The ROHs larger than 1 Mb, 2 Mb, or 3 Mb were 
investigated separately for global burden evaluation, consensus regions, and gene-based analyses.
RESULTS—The African American cohort had a low degree of inbreeding (F ~ 0.006). In the 
Alzheimer’s Disease Genetics Consortium data set, we detected a significantly higher proportion 
of cases with ROHs greater than 2 Mb (P = .004) or greater than 3 Mb (P = .02), as well as a 
significant 114-kilobase consensus region on chr4q31.3 (empirical P value 2 = .04; ROHs >2 Mb). 
In the Chicago Health and Aging Project–Indianapolis Ibadan Dementia Study data set, we 
identified a significant 202-kilobase consensus region on Chr15q24.1 (empirical P value 2 = .02; 
ROHs >1 Mb) and a cluster of 13 significant genes on Chr3p21.31 (empirical P value 2 = .03; 
ROHs >3 Mb). A total of 43 of 49 nominally significant genes common for both data sets also 
mapped to Chr3p21.31. Analyses of imputed SNP data from the entire data set confirmed the 
association of AD with global ROH measurements (12.38 ROHs >1 Mb in cases vs 12.11 in 
controls; 2.986 Mb average size of ROHs >2 Mb in cases vs 2.889 Mb in controls; and 22% of 
cases with ROHs >3 Mb vs 19% of controls) and a gene-cluster on Chr3p21.31 (empirical P value 
2 = .006-.04; ROHs >3 Mb). Also, we detected a significant association between AD and CLDN17 
(empirical P value 2 = .01; ROHs >1 Mb), encoding a protein from the Claudin family, members 
of which were previously suggested as AD biomarkers.
CONCLUSIONS AND RELEVANCE—To our knowledge, we discovered the first evidence of 
increased burden of ROHs among patients with AD from an outbred African American 
population, which could reflect either the cumulative effect of multiple ROHs to AD or the 
contribution of specific loci harboring recessive mutations and risk haplotypes in a subset of 
patients. Sequencing is required to uncover AD variants in these individuals.
In addition to the causal early-onset Alzheimer disease (AD) genes (APP, PSEN1, and 
PSEN2) accounting for only 1% to 3% of patients,1 variations of modest effect in more than 
25 loci have been found to be significantly associated with late-onset AD (age >65 years), 
among them APOE has the largest effect.2 These loci were mainly detected by genome-wide 
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association studies (GWASs) using common single-nucleotide polymorphisms (SNPs) with 
a minor allele frequency greater than 5%, while the search for rare pathogenic mutations 
among them is still ongoing.3 Notably, except for the 2 rare recessive mutations in APP 
(p.A673V4 and E693Δ5), approximately 200 mutations in the 3 causal AD genes all cause a 
dominant early-onset form of the disease,6 which is in contrast to a previous suggestion of 
up to approximately 90% recessive inheritance for early-onset AD.7
Recessive inheritance of complex phenotypes (eg, late-onset AD) can be linked to the 
presence of long runs of homozygosity (ROHs) detectable by SNP arrays used in GWASs. 
Runs of homozygosity could be the result of enhanced inbreeding in previous generations7-9 
or suppressed recombination by a large inversion leading to an extended haplotype (eg, at 
the MAPT locus10). Based on whole-exome data, long ROHs were reported to be 
significantly enriched for potentially deleterious homozygous mutations.11,12 Because small 
ROHs are too frequent and less likely to harbor rare recessive variants, most studies have 
investigated ROHs greater than 1 megabase (Mb) or several cutoffs (eg, ROH>2 Mb or >3 
Mb)13 that could reveal hidden associations by excluding outliers.
Hence, genome-wide study of ROHs could identify cases with a higher probability of 
disease-associated rare recessive mutations or risk haplotypes. We previously showed that 
the global burden measurements of ROHs are significantly associated with AD in an inbred 
population of Caribbean Hispanic individuals, in which the average length of ROHs was 
significantly larger in cases than control participants (P = .004), and this association was 
stronger with familial AD (P < .001).8 Although inbred populations are more powerful for 
ROH study, in some outbred populations, ROHs were associated with several neurological 
disorders including Parkinson disease,14 amyotrophic lateral sclerosis,15 and 
schizophrenia.16
Because studies of 2 outbred AD data sets of North American and European origin did not 
detect an association between AD and ROHs,13,17 we focused our investigation on African 
American individuals, who have a risk for AD up to 3 times higher than in white 
individuals18 and their first-degree relatives with AD have a higher risk for dementia than 
those of white individuals with AD.19 As a result, AD is the fourth leading cause of death 
among African American individuals.18 Our investigation was also motivated by significant 
findings in a Caribbean Hispanic population that has substantial West African heritage.8 
However, a large data set is needed because studies of African American individuals is 
complicated by a high level of genetic divergence owing to their multiple sites of origin, 
mainly from West or Central Africa.20
Therefore, we conducted an ROH study of a large data set of African American patients 
with late-onset AD, consisting of 10 case-control cohorts previously genotyped on 6 
different SNP arrays. The entire data set was previously evaluated by the Alzheimer’s 
Disease Genetics Consortium (ADGC) in an SNP-based GWAS, which replicated several 
AD loci (eg, ABCA7, CR1, BIN1, EPHA1, and CD33).21 We evaluated global and locus-
based ROH measurements by analyzing raw genotypes from 2 independent African 
American cohorts that were grouped based on their genotyping arrays. To maximize the 
statistical power of our study that is dependent on both sample size and SNP density, we 
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also investigated the entire data set (1917 cases and 3858 control individuals) using imputed 
SNP data from different genotyping arrays. Notably, SNP imputation has been suggested to 
be a reliable approach for ROH studies.9
Methods
Genotyping Data
Details of the African American data sets, genotyping arrays, and quality-control steps were 
reported previously.21 The data sets for the study were approved for analysis by the 
institutional review board at the University of Pennsylvania, Philadelphia, and all 
participants provided written informed consent.
STRUCTURE22 analysis was performed to identify hidden population substructure and 
remove outliers. We studied nonimputed data from 2 cohorts that were grouped based on 
their genotyping platforms. The first data set (called ADGC) was genotyped at Children’s 
Hospital of Philadelphia (72.8% female; 36.5% APOE ε4 carriers) using the Human 1M 
Duo Bead Chip (Illumina Inc) that provided genotypes for 965 226 SNPs used for the ROH 
analyses. After removing 90 population outliers from the ADGC data set, 871 cases and 
1620 control individuals were included in the study (eFigure 1A in the Supplement). The 
second data set consisted of merged data from the Chicago Health and Aging Project 
(CHAP) (65.8% female; 38.4% APOE ε4 carriers) and the Indianapolis Ibadan Dementia 
Study (IIDS) (65.6% female; 36.3% APOE ε4 carriers). All samples in the CHAP-IIDS data 
set were genotyped on the Illumina 1M platform (Illumina Inc) that provided genotypes for 
787 726 SNPs for the ROH analyses. After removing 76 population outliers, 279 cases and 
1367 control individuals were included in the study (eFigure 1B in the Supplement).
The ROH analyses were also conducted for the entire data set using imputed SNP data from 
all 10 cohorts. Genome-wide imputation of allele dosages to select the final SNP set for 
analyses (R2≥0.50) was previously done using the June 2011 panel from the 1000 Genomes 
build 37.21 IMPUTE223 files were converted to PLINK24 input files using the GTOOL 
program (http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html). We excluded 
SNPs and individuals with more than 2% missing genotypes, as well as SNPs with a minor 
allele frequency of 5% or less in the entire data set. After removal of population outliers,21 
we analyzed ROHs among 1917 cases and 3858 control individuals, with a total genotyping 
rate of more than 99% for 2 498 646 SNPs. The degree of inbreeding (F) was estimated by 
the genetic relationship matrix implemented in the GCTA program.25 Linkage 
disequilibrium structure was estimated using Haploview26 and based on the control 
genotype data of each group.
Runs of Homozygosity Analyses
Runs of homozygosity for the nonimputed data were analyzed as previously described,8 
while for the imputed data with many more SNPs, we used 100 (vs 50) SNPs in the PLINK 
sliding window and allowed 2 (vs 1) heterozygous SNPs in the window. The number, as 
well as the total and average length of ROHs, was calculated for each sample. Runs of 
homozygosity larger than 1 Mb, 2 Mb, or 3 Mb were investigated separately13 in 3 types of 
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analyses: (1) global burden evaluation; (2) analysis of consensus regions (>100 kilobase 
[Kb]; >3 SNPs), which were segments shared by all individuals carrying ROHs greater than 
1 Mb at each given locus; and (3) gene-based analysis to estimate which genes were 
intersected by ROHs more frequently in cases vs control individuals.
We obtained P values uncorrected (empirical P value 1) and corrected (empirical P value 2) 
for multiple testing using PLINK. All nominally significant genes were checked if they 
belonged to the 77 genes reported to be associated with the 4 most common 
neurodegenerative disorders, keeping in mind their essential overlap at the clinical, 
neuropathological, and genetic levels.27
Global burden measurements among autosomal chromosomes were investigated with a 1-
tailed test (10 000 permutations) for the number of ROHs, their total and average length per 
individual, and the proportions of cases and control individuals with ROHs. A 1-tailed test 
was used because African American individuals have a high incidence of AD18 and such a 
population is more suitable for the detection of risk but not protective alleles.
Results
Analyses of the ADGC Data Set
Results of the global burden ROH analysis of the ADGC data set (871 cases and 1620 
control individuals) are presented in Table 1. We detected a significantly higher proportion 
of cases with ROHs greater than 2 Mb (P = .004) or greater than 3 Mb (P = .02) compared 
with control individuals. In addition, the global rate of ROHs greater than 2 Mb per person 
was marginally higher in cases than control individuals (P = .05). Analysis of ROH 
consensusregions detected a significant association (empirical P value 1 < .001; empirical P 
value 2 = .04) between AD and a 114-kb locus on chr4q31.3 containing the SH3D19 and 
RPS3A genes (Chr4: 152172448-152286356/hg18flankedbyrs6817611andrs7669180). This 
consensus region was overlapped by ROHs greater than 2 Mb in 7 cases and no control 
individuals (Figure 1A; eTable 1 in the Supplement) and belongs to a single linkage 
disequilibrium block based on Haploview investigation of the ADGC control genotypes 
(eFigure 2 in the Supplement). Gene-based analysis revealed only nominally significant loci, 
including PSEN2 (empirical P value 1 = .003) overlapped by ROHs greater than 1 Mb in 
1.26% of cases (n = 11) vs 0.25% of control individuals (n = 4) and SIGMAR1 (empirical P 
value 1 < .001) overlapped by ROHs greater than 1 Mb in 1.61% of cases (n = 14) vs 0.25% 
of control individuals (n = 4) (Table 2).
Analyses of CHAP-IIDS Data Set
The global burden analyses of ROHs did not reveal significant results in the CHAP-IIDS 
data set, likely owing to the limited number of patients (279 cases and 1367 control 
individuals) (Table 1). However, analysis of consensus regions detected a significant 
association between AD and a 202-kb region on Chr15q24.1, which was overlapped by 
ROHs greater than 1 Mb in 5 cases and no control individuals (empirical P value 1 < .001; 
empirical P value 2 = .02). This region is flanked by SNPs rs12442211 and rs11635599 
(chr15:72032728-72235049/hg18) and contains the STOML1, PML, GOLGA6A, and ISLR2 
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genes (Figure 1B; eFigure 3 and eTable 2 in the Supplement). The ROH grouping function 
of PLINK revealed that 4 of 5 cases with this consensus region have a shared haplotype 
(eTable 2 in the Supplement). Notably, in the gene-based analysis of ROHs greater than 1 
Mb, the genes located at this consensus region generated the top nominally significant 
results (empirical P value 1 < .001), while in the analysis of ROHs greater than 2 Mb, the 
top nominally significant gene was CD2AP (the AD gene detected by GWAS28), which was 
intersected in 3 cases (1%) but no control individuals (empirical P value 1 = .005).
After correction for multiple testing, the only association with AD in the gene-based 
analysis was observed for 13 genes within a 3-Mb region on Chr3p21.31 (PFKFB4, UCN2, 
COL7A1, UQCRC1, TMEM89, C3orf18, HEMK1, CISH, MAPKAPK3, DOCK3, MANF, 
RBM15B, and VPRBP) that were intersected by ROHs greater than 3 Mb more frequently in 
cases (n = 8; 2.9%) vs control individuals (n = 5-6; 0.4%) (empirical P value 1 < .001; 
empirical P value 2 = .03) (Figure 2).
Analyses of the Entire Data Set
Global burden ROH analyses of the entire data set using imputed SNP data from 1917 cases 
and 3858 control individuals revealed a significantly higher rate of ROHs greater than 1 Mb 
in cases vs control individuals (P = .02). Also, the average size of ROHs greater than 2 Mb 
(P = .03) and the proportion of ROHs greater than 3 Mb (P = .006) were significantly higher 
in cases compared with control individuals (Table 1). Of note, analyses of imputed data for 
the ADGC data set confirmed a significantly higher global proportion of cases with ROHs 
greater than 2 Mb (P = .004) or ROHs greater than 3 Mb (P = .002) observed in the 
nonimputed ADGC data, indicating reliability of the ROH results generated based on 
imputed data.
Evaluation of relatedness revealed a low degree of inbreeding for both cases and control 
individuals (F ~ 0.006). Thus, we also conducted the global burden analyses of smaller 
ROHs (>0.5 Mb) that showed significant association of AD with ROH rate (P = .04); 
however, the gene-based analysis did not reveal any significant results after correction for 
multiple testing. In contrast, gene-based analysis of ROHs greater than 1 Mb revealed a 
significant association between AD and the CLDN17 gene on 21q22.11, which was 
intersected by ROHs in 11 cases (0.57%) but no control individuals (empirical P value 1 < .
001; empirical P value 2 = .01) (Figure 3). We also observed a significant gene cluster on 
Chr3p21.31 (empirical P value 2 = .006-.04) that was intersected by ROHs greater than 3 
Mb in approximately 2.4% of cases vs approximately 1% of control individuals (eTable 3 in 
the Supplement). This association was mainly driven by the CHAP-IIDS data set because 
genes from this locus were also significant in the analysis of raw genotypes from the CHAP-
IIDS data set (C3orf18, CISH, COL7A1, DOCK3, HEMK1, MAPKAPK3, PFKFB4, and 
UCN2). Indeed, the genes at the Chr3p21.31 locus became insignificant after the CHAP-
IIDS data set was removed from the entire data set, although a global proportion of ROHs 
greater than 3 Mb remained significantly higher in cases vs control individuals (P = .004).
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Discussion
Our results suggest the existence of recessive AD loci among African American individuals. 
A greater global burden of ROH measurements was detected in the entire (imputed) data set 
and ADGC cohort but not in the much smaller CHAP-IIDS data set (Table 1). To our 
knowledge, this is the first report of an association between AD and ROHs in an outbred 
population (F ~ 0.006), in contrast to the report of Caribbean Hispanic individuals with a 
level of inbreeding similar to second cousins (F ~ 0.02).8,29 The mean total length of ROHs 
among African American individuals from both the ADGC (15 Mb) and CHAP-IIDS (10 
Mb) data sets was comparable with that in Caribbean Hispanic individuals of African origin 
(19 Mb),8 but much less than in Caribbean Hispanic individuals of European origin (40 Mb) 
who have a very high degree of inbreeding (F ~ 0.06),8 likely owing to an increase in 
consanguineous marriages after settlement in the Dominican Republic and Puerto Rico. 
Likewise, the average ROH size for the Caribbean Hispanic individuals of European origin 
was larger (2.1 Mb)8 than for the African American individuals (1.5 Mb), reflecting more 
recombination events in an older African American population.
Locus-based ROH analyses could reveal only a small proportion of the genetic variance 
contributing to AD because we analyzed very rare and sparse ROHs (7-12 per genome; 
Table 1). The significant results observed in the locus-based investigation were unique to 
our African American data set; only 12 nominal genes were detected in both the Caribbean 
Hispanic8 and African American cohorts: NKTR, SEC22C, SS18L2, ZBTB47, SCN5A, and 
RBMS3 (Chr3p22-24); PAX5, ZCCHC7, NFX1, and AQP7 (Chr9p13); and INSR and 
ZNF557 (Chr19p13.2) (eTable 4 in the Supplement). Also, no significant loci were common 
between the ADGC and CHAP-IIDS data sets, which could in part be explained by the 
difference in data set size and the sparse overlap of SNPs between the 2 genotyping arrays. 
In general, replication of the association is expected for common variations (eg, SNPs in 
GWASs with frequency of >5%); however, rare genetic variations (eg, ROHs) with a 
frequency of less than 1% could be unique founder events that might not be observed in 
other data sets.30 Nevertheless, the locus-based analyses detected 61 nominally significant 
genes common to both data sets (eTable 5 in the Supplement), including 49 coding genes, 
with 43 of them located at an approximate 2-Mb region within Chr3p21.31, where genes 
that survived correction for multiple testing were detected in the CHAP-IIDS data set. The 
functional significance of the Chr3p21.31 locus is also supported by its epigenomic 
architecture with a high density of gene regulatory elements according to the map of histone 
modifications obtained by ChIP sequencing of the IMR90 cell line (eFigure 4 in the 
Supplement). Importantly, such loci are enriched in disease-associated genetic variants,31,32 
further encouraging the targeted sequencing of the Chr3p21.31 locus.
Most GWASs’ significant loci (SNP or ROH based) remain to be explained by follow-up 
studies. The molecular basis of genetic association is usually investigated in 3 steps: 
detection of the disease loci followed by its sequencing and functional studies of potentially 
damaging variations. Our study represents the first step that revealed the patients with a 
higher probability of having rare recessive mutations at certain ROH locus, and these 
individuals will be included in the sequencing step. There is also a possibility of a more 
complicated mechanism underlying the observed association, such as the action of risk 
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haplotypes or a cumulative effect of ROHs on AD risk, making it more challenging to 
dissect the molecular basis of the association with ROHs.
Yet, it is essential to conduct follow-up sequencing studies because long ROHs are likely to 
harbor deleterious mutations.11,12 The first priority should be given to significant loci in 
each investigated data set. In addition to the gene cluster on Chr3p21.31, a consensus region 
significantly associated with AD was detected on Chr15q24.1 in the CHAP-IIDS data set 
(empirical P value 2 = .02) and on Chr4q31.3 in the ADGC data set (empirical P value 2 = .
04). Both loci contain good functional gene candidates. For instance, the locus on 
Chr15q24.1 includes PML, which is involved in the pathway of presenilin-APP-PML-p53 
and overexpressed in AD brain,33 while the Chr4q31.3 region includes SH3D19, which is 
implicated in the regulation of the ADAM family of metalloproteins responsible for α-
secretase activity in the amyloid pathway.34-37 Potentially damaging variations reported in 
public databases within both consensus regions are presented in eTable 6 in the Supplement. 
Although the Database of Genomic Variants does not indicate that any large (>1-Mb) 
deletions affect the significant loci identified in our study, gene dosage analyses should be 
included in the follow-up study because, in some instances, ROHs could be the result of 
hemizygous deletions. Notably, recurrent microdeletions at 15q24 could not be responsible 
for the association with AD because such deletions cause a syndrome accompanied by major 
dysmorphic features (OMIM 613406).38,39
Analyses of the entire data set using imputed SNP data confirmed the significant 
contribution of recessive loci in the genetics of AD among African American individuals. 
We observed a higher rate of ROHs greater than 1 Mb per individual (P = .02), larger 
average size of ROHs greater than 2 Mb (P = .03), and a greater proportion of individuals 
with ROHs greater than 3 Mb (P = .006) in cases than control individuals (Table 1). Also, 
gene-based analyses revealed significant association with CLDN17 (empirical P value 2 = .
01) that encodes claudin 17, a member of the claudin family. Claudins were suggested as 
AD biomarkers40 and are important for the formation of tight junctions, particularly at the 
blood-brain barrier, where their expression is altered in AD and vascular dementia.41 Our 
results encourage further investigation of genes responsible for the integrity of the blood-
brain barrier, the disruption of which has been implicated in AD pathogenesis.42,43
Similar to the white population, the APOE ε4 allele contributes to AD risk in a dose-
dependent manner in the African American population.44 However, we and others8,13,17 did 
not observe significant ROHs overlapping APOE, likely owing to frequent recombination 
events at this locus. Indeed, SNP-based GWASs have detected only small, approximately 
70-kb extended APOE haplotypes.45 Nevertheless, several genes associated with 
neurodegenerative diseases were nominally significant including AD genes (PSEN2 and 
CD2AP) and VCP (Table 2). The overlap between different loci implicated in 
neurodegenerative disorders has to be systematically explored because there are many 
similarities that connect these disorders. For instance, VCP mutations have been shown to 
segregate with different disease phenotypes, including dementia (OMIM 601023), and VCP 
has been implicated in several cellular functions, including ubiquitin-dependent protein 
degradation highly relevant to neurodegeneration.46
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Conclusions
We observed a significant enrichment of ROHs among cases with AD, indicating the 
existence of recessive risk factors in African American individuals. So far, investigation of 
AD loci detected by the SNP-based studies have revealed only a few damaging variants (eg, 
in ABCA747 or SORL148). Similarly, AD-associated ROH loci have to be examined by 
targeted sequencing for the presence of rare recessive mutations.11 The complex genetics of 
late-onset AD might also be explained by the cumulative effect of multiple risk haplotypes 
underlying the association between AD and greater global burden of ROHs in our study.
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Figure 1. Significant Results Obtained by Analyses of Consensus Regions
Consensus regions are indicated by red bars containing white arrowheads. A, The consensus 
region detected in the Alzheimer’s Disease Genetics Consortium (ADGC) data set contains 
the SH3D19 and RPS3A genes intersected by runs of homozygosity greater than 2 Mb in 7 
cases (samples 10AD24322, 10AD30747, 11AD35799, 11AD35549, 10AD32217, 
10AD32219, and 11AD35543) and no control individuals. B, The consensus region detected 
in the Chicago Health and Aging Project (CHAP)–Indianapolis Ibadan Dementia Study 
(IIDS) data set contains the STOML1, PML, GOLGA6A, and ISLR2 genes intersected by 
runs of homozygosity greater than 1 Mb in 5 cases (samples PT-J6K8_796, PT-J6L9_937, 
PT-28ZI_899514246, PT-9X4V_537994104, and PT-J7BC_5951) and no control 
individuals.
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Figure 2. Significant Results Obtained by Gene-Based Analyses of the Chicago Health and Aging 
Project (CHAP)–Indianapolis Ibadan Dementia Study (IIDS) Data Set
The top section shows the runs of homozygosity (ROHs) greater than 3 Mb on chromosome 
3 among cases (n = 279) and control individuals (n = 1367). Owing to an unbalanced 
distribution of cases and control individuals, fewer ROHs were observed among cases 
compared with control individuals, except at the Chr3p21.31 locus (section within the 
dashed lines), which was affected by ROHs greater than 3 Mb significantly more frequently 
in cases (2.9%, red bars) compared with control individuals (0.4%, blue bars). The middle 
section shows 2 down-brackets pointing to the significantly overlapped genes. The bottom 
section shows the linkage disequilibrium structure of the Chr3:46500000-52500000/hg18 
region estimated based on control genotypes from the CHAP-IIDS data set. tRNA indicates 
transfer ribonucleic acid; UCSC, University of California–Santa Cruz.
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Figure 3. Significant Results Obtained by Gene-Based Analyses of the Entire Data Set
The CLDN17 gene was intersected by runs of homozygosity (ROH) in 11 cases (red bars) 
but no control individuals (blue bar). CCDS indicates consensus coding sequence; tRNA, 
transfer ribonucleic acid; UCSC, University of California–Santa Cruz.
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Table 1
Global Burden Measurements of ROHs Using 3 Different-Sized Cutoffs
1 Mb 2 Mb 3 Mb
Measurement Affected Unaffected P Value Affected Unaffected P Value Affected Unaffected P Value
ADGC Data Set
Total No. 7178 12 993 … 1032 1700 … 479 755 …
ROH segments per 
genome/individual,
No.
8.24 8.02 .07 1.19 1.05 .05 0.55 0.47 .12
Proportion 0.99 1 >.99 0.66 0.59
.004a 0.32 0.28 .02
Total size of ROH, kb 14 850 13 910 .21 8884 8392 .38 13 490 12 910 .43
Average size of ROH, kb 1624 1579 .12 3274 3264 .46 4751 4739 .48
CHAP-IIDS Data Set
Total No. 1919 9442 … 196 1087 … 66 351 …
ROH segments per 
genome/individual,
No.
6.88 6.91 .56 0.70 0.79 .91 0.24 0.26 .66
Proportion 0.99 0.99 .93 0.48 0.52 .90 0.18 0.18 .50
Total size of ROH, kb 10 480 10 850 .69 5139 5633 .64 7453 9443 .73
Average size of ROH, kb 1487 1506 .67 3133 2993 .19 4997 4818 .36
Imputed Data From the Entire African American Data Set (All 10 Cohorts)
Total No. 23 742 46 715 … 2199 4107 … 824 1412 …
ROH segments per 
genome/individual,
No.
12.38 12.11 .02 1.15 1.07 .09 0.43 0.37 .11
Proportion 1 1 >.99 0.61 0.58 .06 0.22 0.19
.006a
Total size of ROH, kb 18 790 18 080 .10 7401 6828 .25 12 650 12 210 .42
Average size of ROH, kb 1447 1431 .10 2986 2889 .03 4734 4599 .18
Abbreviations: ADGC, Alzheimer’s Disease Genetics; CHAP-IIDS, Chicago Health and Aging Project–Indianapolis Ibadan Dementia Study; 
ROHs, runs of homozygosity; ellipses, no comparison for pure number of ROHs.
a
Results that remain significant even after Bonferroni correction (P < .02) calculated based on the 3 ROH cutoffs.
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Table 2
Nominally Significant Results Obtained in Gene-Based ROH Analyses for the Genes Known to Be Linked 
With Neurodegenerative Disorders
Empirical P Value Frequency, %
ROH Minimum Size Gene Transcript Associated Disease 1 2 Cases Controls
ADGC Data Set
1 Mb HIP1R NM_003959 PD .002 .93 2.30 0.80
PSEN2 NM_000447 AD .003 .90 1.26 0.25
SIGMAR1 NM_001282209 ALS/FTD <.001 .23 1.61 0.25
VCP NM_007126 ALS/FTD .03 >.99 0.92 0.25
2 Mb SIGMAR1 NM_001282209 ALS/FTD .01 .81 0.69 0.06
VCP NM_007126 ALS/FTD .01 .81 0.69 0.06
3 Mb SIGMAR1 NM_001282209 ALS/FTD .046 .99 0.34 0
VCP NM_007126 ALS/FTD .046 .99 0.34 0
CHAP-IIDS Data Set
1 Mb ATXN2 NM_002973 ALS/FTD <.001 .99 10.75 5.27
CD2AP NM_012120 AD .02 >.99 1.08 0.07
2 Mb CD2AP NM_012120 AD .004 .54 1.08 0
3 Mb MEF2C NM_001193350 AD .03 .88 0.72 0
Abbreviations: AD, Alzheimer disease; ADGC, Alzheimer’s Disease Genetics Consortium; ALS, amyotrophic lateral sclerosis; CHAP-IIDS, 
Chicago Health and Aging Project–Indianapolis Ibadan Dementia Study; FTD, frontotemporal dementia; PD, Parkinson disease; ROH, run of 
homozygosity.
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